Lykos Therapeutics is dedicated to improving mental health through the development of innovative therapies, particularly focusing on investigational MDMA-assisted therapy for adults with PTSD. Recognizing the urgent need for new treatment options in mental health, Lykos is committed to destigmatizing these conversations and challenging traditional approaches to mental health care. As a public benefit corporation, Lykos balances the goals of generating shareholder value with a commitment to societal impact, ensuring that decisions reflect the interests of diverse stakeholders, including employees and healthcare providers. With over 30 years of experience in researching psychedelic-assisted therapies, the company values integrity, care, and openness while fostering an inclusive and equitable workplace that supports diverse backgrounds and perspectives. Lykos operates as a distributed team, utilizing technology for collaboration and connection in a dynamic work environment.